35 results
8-K
EX-99.1
IGXT
IntelGenx Technologies Corp.
22 Jul 13
IntelGenx announces submission of ANDA for Buprenorphine/Naloxone Sublingual Film Product for the Treatment of Opiate Addiction
12:00am
”) for approval of a generic formulation of buprenorphine and naloxone Sublingual Film, indicated for maintenance treatment of opioid dependence. The ANDA … payments.
About Suboxone®
The FDA approved Suboxone®in October of 2002 for use in the treatment of opioid addiction. Suboxone®is a registered
424B3
IGXT
IntelGenx Technologies Corp.
12 Aug 13
Prospectus supplement
12:00am
Sublingual Film, indicated for maintenance treatment of opioid dependence. The ANDA was filed by our U.S. based co-development and commercialization partner … of commercialization, in addition to upfront and milestone payments.
The FDA approved Suboxone® in October of 2002 for use in the treatment of opioid
424B3
IGXT
IntelGenx Technologies Corp.
12 Aug 13
Prospectus supplement
12:00am
Sublingual Film, indicated for maintenance treatment of opioid dependence. The ANDA was filed by our U.S. based co-development and commercialization partner … of commercialization, in addition to upfront and milestone payments.
The FDA approved Suboxone® in October of 2002 for use in the treatment of opioid
424B3
jfirruu17wydq0ckil
12 Aug 13
Prospectus supplement
12:00am
424B3
am7tcd
15 Nov 13
Prospectus supplement
12:00am
424B3
n6vmjbjvqh rs
15 Nov 13
Prospectus supplement
12:00am
424B3
r6r 1wg7te0catmcrm1
15 Nov 13
Prospectus supplement
12:00am
424B5
yla8rn t2yb6
17 Oct 18
Prospectus supplement for primary offering
4:17pm
424B5
kvz2wvj5 lrr
18 Oct 18
Prospectus supplement for primary offering
9:48pm